prolonged ketamine exposure [8, 9] , identifying adjunctive/maintenance strategies could be of great value in limiting the duration and number of ketamine treatments necessary to maintain clinical benefit.
In contrast to studies suggesting long-term ketamine exposure negatively impacts cognition [10, 11] , limited exposure may enhance cognitive abilities or at least resolve depression-related cognitive impairment in the short term [12] . Subanesthetic doses of ketamine has been shown to induce neuroplastic changes [13, 14] over periods of hours to days following exposure in rodent models. Evidence suggests that ketamine may also enhance synaptic potentiation in humans [15] . Therefore, it may be possible to exploit this critical period of induced plasticity to initiate attempts at modifying cognitions and behaviors that require synaptic plasticity.
In light of existing data showing cognitive behavioral therapy (CBT) to be highly effective in relapse prevention for depression [16] [17] [18] and in line with the sequential model [19] , we conducted an open-label study to explore the efficacy and feasibility of combining CBT and intravenous ketamine infusions for treatment-resistant depression. We were interested in (1) whether CBT can prolong the antidepressant effects of ketamine in patients who respond to ketamine and (2) whether concurrent CBT improves outcomes in patients who do not have an initial robust response to ketamine. As one of the primary goals of CBT is to learn nonpathological thought patterns, we further speculated that severely depressed patients may be able to engage more meaningfully in CBT shortly following exposure to ketamine, given the drug's purported cognitive-enhancing effects. Hence we investigated the effects of ketamine on cognitive performance as a secondary aim.
Methods

Participants and Procedure
Subjects aged 18-65 years with major depressive disorder were recruited from patients presenting for ketamine treatment at our institution. All subjects signed informed consent, and the protocol was approved by the Yale IRB and registered on www.clinicaltrials. gov (NCT02289248). This open-label trial consisted of two phases. During phase one (ketamine/CBT phase), eligible subjects underwent 4 intravenous ketamine infusions (twice weekly for 2 weeks, based on previous work [5] ) as part of clinical care and were concurrently provided CBT under the research protocol (online suppl. Fig. S1 ; see www.karger.com/doi/10.1159/000457960 for all online suppl. material). Participants were not required to respond during the first phase prior to receiving CBT. The CBT was started 24-48 h following the first ketamine infusion and was provided twice weekly during the first phase (concurrent with the ketamine but on separate days). Thereafter, during the second phase (CBT only phase), CBT was provided weekly for an additional 8 weeks (12 sessions in total). Responders were followed for up to 3 months after study end. Concomitant psychotropic medications were not controlled. Ketamine infusions were delivered at 0.5 mg/kg over 40 min (based on ideal body weight if BMI ≥ 30). Further details of the protocol are found in the online supplement.
Cognitive Behavioral Therapy
The CBT was based on Beck's model and focused on (1) psychoeducation, (2) cognitive restructuring, and (3) behavioral activation/modification. The therapy was delivered by therapists (M.K.F. and L.F.) who received extensive training and certification at the Beck Institute for Cognitive Therapy, have 10 or more years of experience with CBT, and have experience with prior CBT studies [20] [21] [22] . Homework included "Thought Records" and "Activity Charts" to help facilitate the adoption and internalization of CBT principles.
Depression Assessments
Depression severity was assessed at every visit using the Montgomery-Asberg Depression Rating Scale (MADRS) [23] and the Quick Inventory of Depression Symptomatology Self Report (QIDS-SR 16 ) [24] . Response was defined as ≥ 50% in MADRS score from baseline, and remission was defined as a MADRS ≤ 9. Relapse was defined as an increase in MADRS scores to <50% reduction of baseline scores for 2 consecutive weeks [6] .
Cognitive Assessments
To explore ketamine's delayed effects on cognition, participants underwent repeated cognitive testing, examining attention, working and visual memory, processing speed, and verbal memory (www.cogstate.com) [25] . Further details of the cognitive assessments are found in the online supplement.
Data Analytic Method
Data analysis followed strategies of a similar protocol [6] . Changes between two time points for depression severity were calculated using paired t tests. Time to relapse among responders was calculated using the Kaplan-Meier method. Survival analyses were performed for all patients who received at least one CBT session. A general linear mixed-model analysis was used to compare cognitive measures over time within subjects, using changes in depression severity over time as a covariate. Further details of the analytic approach are found in the online supplement.
Results
Demographic and Baseline Clinical Variables
Among the 16 subjects who initiated the protocol (online suppl. Fig. S2 ), the mean age was 42.7 years (SD 13.7) and the mean number of years of education was 16.3 (SD 2.4). Most were female (75%) and Caucasian (93.8%). Most participants (68.8%) had a history of hospitalization and a melancholic depression subtype (68.8%), and a sub-stantial minority (37.5%) had a history of ECT. Ketamine responders had lower baseline MADRS scores compared to nonresponders (29.6 vs. 33.9, t = 2.34, p = 0.035). However, baseline QIDS-SR 16 scores were not different between responders and nonresponders (19.9 vs. 19 .4, t = -0.169, p = 0.869). Ketamine responders and nonresponders did not differ in other clinical or demographic variables ( Table 1 ) . Details of subject retention are found in the online supplement.
Clinical Response and Remission to Ketamine
Of the total sample, 8 subjects (50%) achieved response, while 7 (43.8%) achieved remission. Among those who achieved response, most (6/8, 75%) did so after the initial infusion, while the others responded following the fourth infusion. Among those who remitted, 4 (57.1%) did so after the first infusion, 2 did so following the second infusion, and 1 did so following the fourth infusion.
Among ketamine responders, MADRS gains were generally maintained, with significant differences compared to baseline at all time points throughout the study, even when using a conservative LOCF approach (online suppl. Fig. S3A) . A similar pattern emerged as assessed by the QIDS-SR 16 (online suppl. Fig. S3B ). Ketamine nonresponders showed significant improvements during the first 3 weeks of the protocol but then showed no difference compared to baseline following week 3 (online suppl. Fig. S3A ).
Relapse and Retention of Remission
Among responders, 2 (25%) had relapsed by 8 weeks following the last infusion ( Fig. 1 ) . On longer-term follow-up, the median time to relapse was 12 weeks. Among the 7 ketamine remitters, 3 had retained remission until at least 4 weeks following the final ketamine infusion, and 2 had retained remission by 8 weeks following the last in- fusion (study end), though 5/7 had retained a response at this time point.
Cognition
There were no differences between ketamine responders and nonresponders in cognition measures at baseline (data not shown). After adjusting for changes in depression severity, there was a significant effect of time on cognitive measures in working memory (one-back tasks: t = 2.65, p = 0.008; two-back tasks: t = 2.02, p = 0.043) and visual memory ( t = 3.73, p < 0.001) through the 2 weeks of ketamine infusions (online suppl. Fig. S4 ). There was a slowing in processing speed over time ( t = -2.93, p = 0.003). There were no other significant trends over time in other domains. Details regarding concomitant medications and adverse events can be found in the online supplement (online suppl. Tables S1 and S2).
Discussion
This is the first study examining the ability of CBT to sustain the antidepressant effects of ketamine as well as the first study to examine longer-term outcomes in a substantial cohort of depressed patients treated with ketamine. Our sample was comprised of severely ill treatment-seeking patients, the majority of whom had chronic and melancholic (68.8%) forms of depression, many who had previously received ECT (38.8%). Compared to previous reports [6, 26] , this study found CBT may be effective in extending the duration of the ketamine antidepressant response. While most participants eventually relapsed, the majority did so following completion of the weekly CBT, suggesting a sustained antidepressant response with ongoing CBT. Given the concerns of repeated ketamine exposure, the relapse prevention strategy of the current study shows promise and warrants further study.
The initial clinical response and remission rates are comparable to prior studies [6, 26, 27] . Despite the openlabel nature of our study, our relapse rate of 25% at 8 weeks following the last ketamine infusion compares very favorably to the results of similar open-label protocols, where relapse rates at 4 weeks or earlier following 6 infusions range from 55 to 89% [6, 7, 26] . The median time to relapse in this study (12 weeks) also compares favorably to other studies explicitly designed to examine relapse pharmacotherapeutic prevention strategies where the median time to relapse measures were 17 and 24 days [28, 29] . Vande Voort et al. [27] showed that the antidepressant effects of ketamine could also be extended in early remitters by repeated exposures at weekly intervals. In this study, most (4/5) remitters lost remission status at 4 weeks following the discontinuation of ketamine, but all retained response at that time point; longer-term outcomes were not reported. In our protocol, of 7 remitters, 3 retained remission by 4 weeks after ketamine exposure, and 2 retained remission 8 weeks after ketamine exposure.
As noted, most of the ketamine responders relapsed following the conclusion of the weekly CBT phase of the study. Given that all subjects were treatment resistant and had recurrent forms of MDD, it is possible that a longer course of CBT may have been more effective at modifying negative core beliefs and thus producing a longer relapsefree period after ketamine treatment. Additionally, a longer course of ketamine infusions may also contribute to longer relapse-free periods. Longer courses of both ketamine treatments and CBT should be considered in future studies. Future work with larger sample sizes should also include analyses of baseline predictors of the likelihood of experiencing adverse events as a consequence of this treatment approach [30] . Our small sample size precludes meaningful analyses of subgroups of patients most likely to benefit versus those who would incur harmful adverse events from this approach.
The results of our cognitive assessments were mixed. The improvements seen in working and visual memory replicated those from a prior study [31] , though our study showed these effects over a shorter time period (24-72 h vs. 3 weeks) and survived adjustment for changes in depression severity. However, we observed an unexpected decline in processing speed over time, which is in contrast with prior research [31, 32] . This potential decline may underscore concerns in the field that repeated exposure to ketamine may produce adverse neurocognitive changes [33] . It also serves to emphasize the urgency for strategies to maintain wellness without continued exposure to the drug and the pressing need for research on the safety of longer-term exposure to ketamine [34] . Our small sample size, however, precludes firm conclusions of the effects of ketamine on processing speed.
Several limitations of our study require comment. First, our findings are limited by the small sample size and open-label design. Second, the lack of a control group makes it difficult to interpret whether the antidepressantsustaining effects of psychotherapy were specific to CBT or were due to nonspecific supportive effects. Additionally, the lack of control group makes it difficult to interpret whether cognitive changes were due to a specific effect of ketamine or only the result of practice effects. Third, given that concomitant medications were not controlled, it is possible that any sustained antidepressant effects were due to effects of medication changes; however, the fact that very few of the ketamine responders (25%) made changes to antidepressants during the trial argues against this explanation. Finally, administering ketamine concurrently with CBT may have confounded whether the response was specific to ketamine or was due to the combination of the two treatments; however, the relatively rapid nature of response seen in this study was more characteristic of ketamine than CBT.
Conclusions
Given the concerns of repeated exposure to ketamine, CBT may provide an effective treatment strategy to sustain ketamine's antidepressant effects. Well-powered, randomized trials are warranted to investigate whether this treatment strategy produces sustained effects and minimizes the exposure to ketamine.
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